Clinical trials
Fallopian Tube Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 20 |
| Unknown status | 12 |
| Completed | 10 |
| Not yet recruiting | 7 |
| Active, not recruiting | 6 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai Gynecologic Oncology Group | 11 |
| Genmab | 3 |
| AbbVie | 2 |
| AstraZeneca | 2 |
| Beijing Biotech | 2 |
| Hoffmann-La Roche | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 |
| AGO Study Group | 1 |
| Advenchen Laboratories, LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fallopian Tube Neoplasms | 55 |
| Ovarian Neoplasms | 39 |
| Carcinoma, Ovarian Epithelial | 24 |
| Endometrial Neoplasms | 5 |
| Recurrence | 5 |
| Peritoneal Neoplasms | 4 |
| Uterine Cervical Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Breast Neoplasms | 2 |
| Carcinoma | 2 |
Trials
Showing 76 to 55 of 55. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.